Dr Reddy’s Strikes $67m Deal With Alvotech On Denosumab

Indian Firm Gains Rights In US And Europe; Builds Infrastructure For Biosimilars Unit

 
• By Dave Wallace

Dr Reddy’s has announced a denosumab licensing deal with Alvotech covering the US and Europe, for which the Indian company has broken down the financial details. More broadly, the alliance will also allow Dr Reddy’s to build up its commercial infrastructure for biosimilars in both key markets.

Handshake
Alvotech and Dr Reddy’s are collaborating on denosumab in the US and Europe

Dr Reddy’s has struck a fresh biosimilar commercialization deal, announcing an alliance with Alvotech on denosumab that will give the Indian firm “exclusive commercialization rights in the US as well as semi-exclusive rights in Europe and the UK” to Alvotech’s AVT03 candidate.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business